1 |
Krug U, Gale RP, Berdel WE, et al. Therapy of older persons with acute myeloid leukaemia [J]. Leuk Res, 2017, 60: 1-10.
|
2 |
Tsai CH, Hou HA, Tang JL, et al . Genetic alterations and their clinical implications in older patients with acute myeloid leukemia [J]. Leukemia, 2016, 30(7): 1485-1492.
|
3 |
Jeziskova I, Musilova M, Culen M, et al. Epigenetic guardian: a review of the DNA methyltransferase DNMT3A in acute myeloid leukaemia and clonal haematopoiesis [J]. Biomed Res Int, 2017, 2017: 5473197.
|
4 |
Guryanova OA, Shank K, Spitzer B, et al. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling [J]. Nat Med, 2016, 22(12): 1488-1495.
|
5 |
Stone RM, Lindsley C. Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older [J]. Haematologica, 2018, 103(11): 1853-1861.
|
6 |
刘洁, 华海应, 晁红颖, 等. 急性髓系白血病中DNMT3A p.R882的共存基因突变分析 [J]. 南京医科大学学报, 2020, 40(9): 1331-1337.
|
7 |
秦伟, 晁红颖, 蔡晓辉, 等. 伴NPM1突变的老年急性髓系白血病患者的共存基因突变分析[J]. 中华医学杂志, 2019, 99(40): 3152-3157.
|
8 |
Green CL, Koo KK, Hills RK, et al. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations [J]. J Clin Oncol, 2010, 28(16): 2739-2747.
|
9 |
张修文, 周民, 晁红颖, 等. 150例原发性血小板增多症患者CALR基因突变检测及临床观察[J]. 中华血液学杂志, 2015, 36(5): 378-382.
|
10 |
Xing S, Wang B, Gao Y, et al. Cytogenetics and associated mutation profile i patients with acute monocytic leukemia [J]. Int J Lab Hematol, 2019, 41(4): 485-492.
|
11 |
Cheng Z, Dai Y, Pang Y, et al. Importance of prognostic stratification via gene mutation analysis in elderly patients with acute myelogenous leukemia [J]. Int J Lab Hematol, 2019, 41(4): 461-471.
|
12 |
Yang XR, Shi JL, Zhang XP, et al. Biological and clinical influences of NPM1 in acute myeloid leukemia patients with DNMT3A mutations [J]. Cancer Manag Res, 2018(10): 2489-2497.
|
13 |
Zhao CX, Wang JM, Li JM, et al. Comparison of gene mutation spectra in younger and older Chinese acute myeloid leukemia patients and its prognostic value [J]. Gene, 2020, 770: 145344.
|
14 |
王卫敏, 李亚飞, 孙玲, 等. 基于二代测序的老年和年轻成人急性髓系白血病患者突变基因谱比较 [J]. 中国实验血液学杂志 ,2020, 28(1): 12-17.
|
15 |
Ohgami RS, Ma L, Merker JD, et al. Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1 [J]. Blood Cancer J, 2018, 8(1): 4.
|
16 |
Ahn JS, Kim HJ, Kim YK, et al. DNMT3A R882 mutation with FLT3-ITD positivity is an extremely poor prognostic factor in patients with normal-karyotype acute myeloid leukemia after allogeneic hematopoietic cell transplantation [J]. Biol Blood Marrow Transplant, 2016, 22(1): 61-70.
|
17 |
Renneville A, Boissel N, Nibourel O, et al. Clinical implications of DNMT3A mutations in a Southeast Asian cohort of acute myeloid leukaemia patients [J]. J Clin Pathol, 2017, 70(8): 669-676.
|
18 |
Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia [J]. N Engl J Med, 2016, 374(23): 2209-2221.
|
19 |
Sato H, Wheat JC, Steidl U, et al. DNMT3A and TET2 in the pre-leukemic phase of hematopoietic disorders [J]. Front Oncol, 2016, 6: 187.
|
20 |
Montalban-Bravo G, DiNardo CD. The role of IDH mutations in acute myeloid leukemia [J]. Future Oncol, 2018, 14(10): 979-993.
|
21 |
Wang R, Gao X, Yu L. Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype [J]. Haematologica, 2015, 100(9): e351-353.
|
22 |
Paschka P, Schlenk RF, Gaidzik VI, et al. The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML [J]. Am J Hematol, 2019, 94(8): 913-920.
|
23 |
Yang X, Shi J, Zhang X, et al. Clinical and biological implications of IDH1/2 in acute myeloid leukemia with DNMT3Amut [J]. Cancer Manag Res, 2018, 10: 2457-2466.
|
24 |
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [J]. Blood, 2016, 127(20): 2391-2405.
|